PPARA and Insulin resistance: chiglitazar sodium, a PPAR agonist, activates PPARα, γ, δ, reduces insulin resistance, effectively controls blood sugar and improves the disorder of blood lipid and energy metabolism often associated with T2DM patients, with good safety.